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Psychosis is a major mental illness with first onset in young adults. The prognosis is poor in 
around half of the people affected, and difficult to predict. The few tools available to predict 
prognosis have major weaknesses which limit their use in clinical practice. We aimed to 
develop and validate a risk prediction model of symptom non-remission in first-episode 
psychosis. Our development cohort consisted of 1027 patients with first-episode psychosis 
recruited between 2005 to 2010 from 14 early intervention services across the National 
Health Service in England. Our validation cohort consisted of 399 patients with first-episode 
psychosis recruited between 2006 to 2009 from a further 11 English early intervention 
services. The one-year non-remission rate was 52% and 54% in the development and 
validation cohorts, respectively. Multivariable logistic regression wa  used to develop a risk 
prediction model for non-remission, which was externally validated. The prediction model 
showed good discrimination (C-statistic of 0.73 (0.71, 0.75) and adequate calibration with 
intercept alpha of 0.12 (0.02, 0.22) and slope beta of 0.98 (0.85, 1.11). Our model improved 
the net-benefit by 15% at a risk threshold of 50% compared to the strategy of treating all, 
equivalent to 15 more detected non-remitted first-episode psychosis individuals per 100 
without incorrectly classifying remitted cases. Once prospectively validated, our first episode 
psychosis prediction model could help identify patients at increased risk of non-remission at 
initial clinical contact.  
 





















Psychotic disorders, including schizophrenia, are among the 20 leading causes of disability 
worldwide in 2017. People with psychosis have heterogeneous outcomes with more than 
40% not achieving symptomatic remission.1  Symptom remission after the first episode of 
psychosis (FEP) is associated with long term functional outcome.2 The main modifiable 
reasons for non-remission include treatment resistance3, medication non-adherence4 and 
comorbid substance misuse.5 Although there are effective interventions to ameliorate the 
reasons for non-remission, there is often a delay in providing these interventions. For people 
with treatment-resistant psychosis, delays of around four years in initiating effective 
interventions have been reported – for example, clozapine for treatment resistance.6 Delay is 
associated with poorer outcomes. Clinicians have identified the difficulty of early 
identification of patients likely to become treatment-resistant as a barrier preventing the 
initiation of effective phase-specific treatments like clozapine at the optimal time.7  
Early identification of individuals with a higher risk of non-remission at initial clinical contact 
may facilitate personalized interventions, reduce time to their initiation and improve utilization 
of resources.  Although there have been recent attempts to develop models to predict the 
individual risk of poor outcome in FEP8–10, these are affected by suboptimal study design 
and reporting, lack of external validation8, small sample sizes9, and no measures of 
calibration or clinical utility.8–10 This study aimed to develop and externally validate a new 
prediction model to predict the individual risk of non-remission at one-year for individuals 
with first-episode psychosis. 
Methods 
Data sources and study population 
We used data from the National Evaluation of Development of Early intervention Network 


















Outlook study for external validation. Written informed consent was obtained from all 
participants. Both studies had NHS Research Ethics Committee approval. 
Development cohort 
NEDEN is a longitudinal naturalistic study of 1027 patients aged 14-35 with FEP recruited 
from 14 early intervention services across the National Health Service (NHS) in England 
(2005–10); the methods and baseline characteristics have been outlined previously.11 An 
analysis of the potential of prediction modelling in FEP using this dataset has been 
published. We conducted a reanalysis to address methodological issues with our previous 
analysis10 (including the lack of any measures of calibration or clinical utility) and to take 
advantage of an external validation dataset which was similar to the development dataset (in 
terms of patients, geography and clinical service they were drawn from) allowing for better 
assessment of generalizability. Models in the previous analysis did not inform the present 
study. 
Validation cohort 
The Outlook study (which was part of the PsyGrid study) is a longitudinal naturalistic 
study of 399 patients recruited from a further 11 NHS England early intervention 
services, throughout April 2006-February 2009.12 Inclusion criteria: age 16-35, 
International Classification of Diseases 10th Revision (ICD-10) diagnosis of 
schizophrenia, schizoaffective disorder, delusional disorder, mania or severe 
depression with psychosis, acute and transient psychoses, drug-induced psychoses 
and psychosis not otherwise specified; those with organic brain disorders were 
excluded. 
In both cohorts, participants were recruited as soon after the first contact with the 


















referral was received by a participating service, regardless of whether the potential 
participant was in the hospital or the community.   
Outcome measure 
Our outcome measure was symptom non-remission at one-year. Non-remission was defined 
as failing to meet the Remission in Schizophrenia Working Group criteria using the Positive 
And Negative Syndrome Scale (PANSS) at six and twelve-months, a reliable and valid scale 
in clinical and research settings. The Remission in Schizophrenia Working Group defined 
remission as scores of less than or equal to 3 in PANSS items P1 Delusions, P2 Conceptual 
Disorganization, P3 Hallucinatory Behavior, N1 Blunted Affect, N4 Apathetic Social 
Withdrawal, N6 Lack of Spontaneity and G9 Unusual Thought Content, present for a period 
of at least 6 months.13 
Candidate predictors 
In both cohorts, psychologists not directly involved in clinical care trained in the use of the 
rating scales assessed participants at baseline, six- and twelve-months follow-up. Both 
studies collected candidate predictors based on existing literature and expert knowledge 
using standardized assessment instruments. These included sociodemographic and clinical 
variables, the Premorbid Adjustment Scale, PANSS,  Young Mania Rating Scale, Birchwood 
Insight Scale, Calgary De ression Scale for Schizophrenia, Global Assessment of 
Functioning and EQ-5D. In addition, participant UK postcode outward code was mapped to 
primary care trust (PCT). Summary PCT level UK Government Index of Multiple Deprivation 
(IMD) data (collected between 2001 and 2005, released 2007) was then linked to each 
patient.  
14 predictors were chosen based on previous research and consensus between 5 
psychiatrists working in the field of Early intervention in Psychosis. The list of predictors is 


















performed using the NEDEN dataset.13 This did not influence the choice of predictors for the 
present study. 
Sample size calculation 
Using Riley et al.’s 14 criteria for multivariable prediction model development for binary 
outcomes, the minimum sample size required given a 50% prevalence of non-remission with 
14 predictor parameters (meeting the assumptions of global shrinkage factor of 0.90, an 
absolute difference of  0.05 between apparent and adjusted R-squared, and a 0.05 margin 
of error in the estimation of intercept) is 431 with 216 non-remitters (Events per Predictor 
Parameters (EPP) =15). Our development cohort included 673 FEP individuals with 353 
individuals meeting criteria for non-remission at one-year. This provides an EPP of 25, which 
is above requirements. Further, the number of non-remission events in both the 
development and validation cohort was >100, which is in line with suggested criteria 15. The 
number of non-events in the validation cohort was 88, just below suggested criteria. 
Missing data  
Missing data were multiply imputed (m=10) by chained equations using all predictors, 
auxiliary variables, and outcomes based on the assumption that data was missing at 
random. Imputed outcome data was then deleted16. It is proposed that this strategy leads to 
more efficient estimates than an ordinary multiple imputation strategy while also protecting 
the estimates from problematic imputations in the outcome variable15. This multiple 
imputation strategy was carried out separately for the development and validation datasets. 
Ordinal variables were treated as continuous and binary variables were dummy coded. All 
predictor variables were standardized prior to model construction.  
Statistical analysis for model development 
We followed the TRIPOD (Transparent Reporting of a multivariable model for Individual 



















Model Development, Internal and External validation 
A logistic regression model was fitted by maximum likelihood estimation on the 14 chosen 
predictors. Internal validation performance was assessed by ten-fold cross-validation 
repeated five times on the ten imputed datasets. The model performance was considered 
using discrimination and calibration measures. Discrimination, or the ability of our model to 
distinguish a patient with the outcome (non-remission) from a patient without (remission), 
was assessed via the C-statistic (with 95% CIs were established via U-statistic theory and 
permutation testing to confirm significance). Calibration is the level of agreement between 
the observed outcomes and the model's predictions. Two measures of model calibration 
were calculated: calibration-in-the-large (alpha) which is the intercept on the calibration plot 
and compares mean observed to mean predicted, and, the calibration slope (beta) which 
relates to the shrinkage of the regression coefficients. A perfectly calibrated model would 
show an ideal line with intercept alpha of 0 and a slope beta of 1. For internal validation, only 
the slope beta is of value and corresponds to the shrinkage factor or measure of overfitting.18 
This uniform shrinkage factor was applied to the final logistic regression model and the 
intercept was re-estimated prior to external validation on the Outlook dataset.  
Clinical utility 
Clinical utility was assessed in the external validation cohort, in addition to discrimination and 
calibration. We assessed the clinical usefulness of using a treatment strategy based on the 
prediction model compared with treating all, treating none or treating based on the duration 
of untreated psychosis (DUP) alone (DUP is the most researched and consistent predictor of 
poor outcome in FEP). Hereto, a decision curve analysis was performed.19 Clinical 
usefulness is considered in terms of net-benefit (the treatment threshold weighted sum of 
true- minus false-positive classifications for each strategy) plotted against an entire range of 
treatment thresholds. A treatment threshold is defined as the point where the likelihood of 


















Treatment thresholds vary between individual clinicians and patients depending on their 
context-specific weighting of relative harms and benefits.  
            
              
 
   
               
 
   
                    
                       
 
N = total sample size 
The intervention (‘treatment’) proposed on the prediction of a high risk of non-remission is 
‘enhanced monitoring’ over routine care leading to early identification and intervention for 
treatment resistance, substance misuse or non-concordance. To use a prediction model for 
such treatment decisions, we require to specify a probability threshold above which we 
would consider the treatment.  
We consulted NHS early-intervention specialists (eight NHS Consultant Psychiatrists) to 
ascertain the probability threshold at which they would consider treatment. The range of 
thresholds varied between 40-60% That is; they would adopt an assertive monitoring and 
intervention approach when an individual’s probability of non-remission is above 40-60% to 
balance the likelihood of benefits versus the harms/costs (in this case, the benefit of reduced 
rates of non-remission against the probability of harm via intrusive monitoring, side-effects, 
and increased costs). 
Net-benefit is calculated across the range of threshold probabilities of the outcome (non-
remission) at which further intervention would be warranted. Net-benefit differs from other 
performance metrics such as discrimination and calibration because it incorporates the 
consequences of the decisions made based on a model. 
All analyses were performed using R , CRAN version 4.1.020 (with the ‘mice’21 ‘caret’22, 
‘pROC’23, ‘CalibrationCurves’ and ‘dca’ packages) and code are available online. The 





















In the NEDEN study, 673 (66%) of 1027 participants had outcome data, of which 353 (52%) 
met criteria for one-year symptom non-remission. In the Outlook study, 191 (48%) of 399 
participants had outcome data, of which 103 (54%) met criteria for non-remission. The 
baseline characteristics of the development (NEDEN) and validation (Outlook) cohorts are 
summarized in Supplementary Table 1. 
Model development and internal validation 
The 14 variable logistic regression prediction model is specified in Table 1. 
At internal validation, the discrimination C-statistic was 0.74 (0.73, 0.75) while the calibration 
slope beta of 0.84 (0.81, 0.86). This shrinkage factor was applied to the final model 
coefficients and the intercept was re-estimated. 
External validation 
At external validation, the model showed fair discrimination with a C-statistic of 0.73 (0.71-
0.75). There was a good spread of risk, with good correspondence between observed 
proportions with psychosis for subjects grouped by similar predicted risk (Figure 2).  
For the Outlook external validation, the 54% overall rate of non-remission at one-year 
implies a maximal net-benefit of 54% at a decision threshold for treatment of 0%. Figure 3 
shows that, between thresholds of 30%-75%, treating based on our model is better than 
treating all or treating using DUP alone. At a probability threshold of 50% (mid-point of the 
range of clinician chosen thresholds), treating based on our model has an increased net-
benefit of 15% compared the strategy of treating all, equivalent to 15 more detected non-
remitted FEP individuals per 100 FEP individuals without an increase in incorrect 




















We have developed a new risk prediction model based on baseline demographic and clinical 
variables to predict the risk of non-remission at one-year after the onset of first-episode 
psychosis in a large sample of FEP individuals. The model was validated across services in 
the development population and externally validated on an independent cohort. The 
prediction model had fair discrimination and was well-calibrated. The model showed an 
increase in net-benefit.  
Strengths and weakness of the study 
Our study has some strengths. Both our development and validation cohorts included a 
representative sample of FEP participants from early intervention services in England, who 
were prospectively followed up for a year. Both the cohorts were assembled in similar 
services (early intervention) and periods in England which improves generalizability to 
patients within these services, though they have potentially changed in the past ten years 
resulting from financial austerity measures. The candidate predictors and outcomes were 
measured using standardized instruments by graduate psychologists who were not directly 
involved in the care of the participants, which minimized the measurement bias. We used an 
operationalized, and well-established outcome definition for non-remission, which further 
minimizes measurement bias. We provided four measures of model performance – 
discrimination, two measures of calibration and decision curve analysis.18 Though the 
baseline measures were meant to be measured on the first presentation to EIS, in practice, 
there was variation: in NEDEN 32% within three weeks of presentation; in Outlook 21% 
within three weeks. The model will apply to patients at least three weeks after their 
presentation to early intervention services. 
There are some weaknesses to the study. Ethnicity was not included as a predictor in our 
model. This is some evidence that treatment resistance may be predicted by ethnicity.3 Only 


















may affect the generalizability of our models to the general FEP population. However, those 
who did not consent were largely similar at baseline to people who did.11 Outcome data was 
not available for 34% of the NEDEN cohort and 52% in the Outlook cohort, which could 
further limit the validity of the results. As a result, while the number of events in the validation 
cohort was >100 (103), the number of non-events was <100 (88). This is slightly less than 
suggested criteria. The method used for imputation of missing predictors using all the 
available data including outcome data and deletion of imputed outcome data has the 
advantage of the predictor imputation benefitting from the full data structure, whilst protecting 
the regression estimates from often problematic outcome imputations15. This approach has 
been subject to criticism24, though it is recognized that outcome imputation remains 
controversial. Further, there were differences in rates of missing data between the 
development and validation datasets. The outcome was measured only at the six and 12-
month time points. Study subjects may not have met remission criteria for the entire six 
months in between. The cohorts did not collect biomarkers of illness including inflammatory 
or neuroimaging data which a previous study in clinical high-risk populations has found to 
increase prognostic certainty when added to models based on clinical variables.25 Another 
weakness is that we have not accounted for treatment effects, which can lead to suboptimal 
model performance, albeit only in the presence of strong treatment effects. We assumed that 
standardized treatment was provided to all participants as they were drawn from early 
intervention services.  
Comparison with previous studies 
Three prediction models for outcome in first-episode psychosis have been reported, though 
they are yet to be used in clinical practice. One study has examined the prediction of social 
recovery in FEP participants from an RCT8, whilst the other two studies have examined 
prediction for remission and recovery measures in cohort studies.9,10 The discrimination 
performance for the remission outcome in our study is higher than that reported for models 


















internal and external validation respectively 10), which could be explained by the smaller 
sample sizes used in their development and validation9, and the higher number of predictors 
used for their model development10. Measures of calibration and clinical usefulness have not 
been provided by the other two studies, which adds to the novelty and importance of the 
current study. 
Implications for clinicians and policymakers 
The early identification of FEP individuals with higher risk prediction of non-remission may 
allow for changes to their treatment strategies, leading to improved remission rates. Though 
suggestions for such a strategy to improve remission rates have been made previously, 
there have been limited attempts towards a targeted approach to identify FEP individuals at 
high risk of non-remission.  
Health services globally has introduced measures to improve access to services and to 
ensure that FEP individuals receive evidence-based care. A validated prediction model 
closely aligns with the policy agenda of early identification of FEP individuals with a high risk 
of non-remission so that their care can be optimized, and resources targeted according to 
need.  
Future research 
Prospective validation in additional cohorts from plausibly related settings is required to 
establish the utility of our model in clinical settings. This will help to compare the model 
predictions versus clinical intuition and address the issue of treatment effect. Future 
research also needs to address what biomarkers, such as neuroimaging and immune 
markers, add to the performance of the model. The model should be validated in a range of 
clinical settings for its use in services outside England, and in settings that do not have early 
intervention psychosis services, which may show a need for local updating to improve the 
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Figure 1 – Analysis pipeline 
Figure 2 – External validation calibration plot.  The calibration was near ideal with an 
intercept of 0.12 (0.02, 0.22) and slope 0.98 (0.85, 1.11). Triangles represent quintiles of 
subjects grouped by similar predicted risk. The distribution of subjects is indicated with 
spikes at the bottom of the graph, stratified by endpoint (non-remitters above the x-axis, 
remitters below the x-axis). 
Figure 3 - External validation decision curve analysis plot. Net-benefit is the treatment 
threshold weighted sum of true- minus false-positive classifications for each strategy plotted 
against an entire range of treatment thresholds. Green line: no patients are treated, net-
benefit is zero (no true-positive and no false-positive classifications); red line: all patients are 
treated; purple and cyan lines: patients are treated if predictions exceed a threshold, with 
non-remission predictions based 
on adjusted DUP only, or on our prediction model. Between thresholds of 30%-75%, treating 



















Table 1 – The final logistic regression non-remission prediction model specification 
Variable Unadjusted Final Model 
 
Adjusted Final Model 





β Coefficient Odds Ratio 
Intercept 0.022 
(-0.334, 0.379) 
 0.029  




































































Insight Scale – 

























DUP = duration of untreated psychosis; PAS = premorbid adjustment scale; PANSS = 
Positive and Negative Syndrome Scale; GAF = Global Assessment of Functioning; PCT = 
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